Last reviewed · How we verify
Advancing People of Color in Clinical Trials Now: Involvement in Trials Using a Patient-Centered Website: A Community-Engaged Approach
NA trial testing Tailored Website in Recruitment in 112 participants. Completed in 28 April 2019.
| Lead sponsor | NYU Langone Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 112 |
| Start date | 14 August 2017 |
| Primary completion | 28 January 2019 |
| Estimated completion | 28 April 2019 |
| Sites | 1 location across United States |
NYU Langone Health — full company profile →
18 and older, any sex, with Recruitment. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
26 statements involved in assessing the participants' knowledge of clinical trials. The total range of score is 0-104; the higher the score, the higher the level of knowledge.
| Group | Value | 95% CI |
|---|---|---|
| Intervention Group (Pair 1) | 93.89 | ± 9.98 |
| Intervention Group (Pair 2) | 93.58 | ± 9.69 |
| Control Group (Pair 3) | 94.88 | ± 11.80 |
| Control Group (Pair 4) | 97.88 | ± 11.45 |
26 statements involved in assessing the participants' knowledge of clinical trials. The total range of score is 0-104; the higher the score, the higher the level of knowledge.
| Group | Value | 95% CI |
|---|---|---|
| Intervention Group (Pair 1) | 101.89 | ± 10.37 |
| Control Group (Pair 3) | 99.67 | ± 10.94 |
26 statements involved in assessing the participants' knowledge of clinical trials. The total range of score is 0-104; the higher the score, the higher the level of knowledge.
| Group | Value | 95% CI |
|---|---|---|
| Intervention Group (Pair 2) | 98.00 | ± 11.99 |
| Control Group (Pair 4) | 98.32 | ± 8.46 |
A 4-item perceived effectiveness scale was used to assess the perceived persuasiveness of the message. The total range of score is 0-16; the higher the score, the higher the level of self-efficacy.
| Group | Value | 95% CI |
|---|---|---|
| Intervention Group (Pair 1) | 10.13 | ± 4.19 |
| Intervention Group (Pair 2) | 10.06 | ± 4.49 |
| Control Group (Pair 3) | 11.16 | ± 3.08 |
| Control Group (Pair 4) | 11.04 | ± 3.08 |
A 4-item perceived effectiveness scale, adapted from Fishbein et al. (2002) was used to assess the perceived persuasiveness of the message. The total range of score is 0-16; the higher the score, the higher the level of self-efficacy.
| Group | Value | 95% CI |
|---|---|---|
| Intervention Group (Pair 1) | 12.06 | ± 3.35 |
| Control Group (Pair 3) | 12.02 | ± 3.40 |
A 4-item perceived effectiveness scale, adapted from Fishbein et al. (2002) was used to assess the perceived persuasiveness of the message. The total range of score is 0-16; the higher the score, the higher the level of self-efficacy.
| Group | Value | 95% CI |
|---|---|---|
| Intervention Group (Pair 2) | 12.42 | ± 3.40 |
| Control Group (Pair 4) | 11.88 | ± 3.10 |
The purpose pf this study is to evaluate the comparative effectiveness of a culturally and linguistically tailored clinical trial literacy website in increasing likelihood of participating in clinical trials. To achieve this objective,a randomized group design will address the following patient-centered outcomes: willingness to enroll in clinical trials and behavioral intent as well as likelihood of referring others to enroll in such trials) before and after exposure to a culturally-tailored clinical trial literacy website. Health literacy will be measured both before and post exposure to tailored messages. Participants will be randomized into two groups. The intervention group (n=50) will have access to culturally tailored website. Participants in the control group (n=50) will have access to NYU 's standard trial participation website.
1 peer-reviewed publication reference this trial (live from Europe PMC):
Verify or expand the search:
Currently open trials in the same condition.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03243071.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing